J

Johnson & Johnson

Makes prescription drugs and medical devices

Overview

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Work here?Claim your company

About Johnson & Johnson

Simplify's Rating
Why Johnson & Johnson is rated
B+
Rated A on Competitive Edge
Rated B on Growth Potential
Rated B on Differentiation

Industries

BiotechnologyHealthcare

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, NJ

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Stock Price

Growth & Insights and Company News

6 month growth

2%

1 year growth

-1%

2 year growth

-1%
Yahoo Finance
Nov 6th, 2026
Average 1-year CD pays 1.76%, while dividend stocks like Realty Income yield 5.21%

The average 1-year certificate of deposit (CD) paid 1.76% on October 1, 2026, according to the Federal Deposit Insurance Corporation (FDIC). That is well below the Federal Reserve's target range, whose upper bound was 4.00% as of November 6. Some savers are weighing blue-chip dividend stocks instead. Realty Income yields 5.21% and Verizon 6.22%, while Procter & Gamble yields 2.65%, Coca-Cola 2.13%, and Johnson & Johnson 1.91%. Microsoft yields 0.67%. A CD rate is locked for the term, but a dividend can grow or be cut. Qualified dividends are taxed at 0%, 15%, or 20%, while CD interest is taxed as ordinary income.

Yahoo Finance
Nov 6th, 2026
FDA approves J&J's Rybrevant Faspro, first dual-targeted therapy for head and neck cancer

Johnson & Johnson said the US Food and Drug Administration (FDA) granted accelerated approval to RYBREVANT FASPRO, a subcutaneous injection, for adults with recurrent or metastatic head and neck squamous cell carcinoma. The drug is for patients whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. It excludes HPV-associated oropharyngeal cancer. It is the first dual-targeted therapy in this setting, hitting both the EGFR and MET pathways. It is also the drug's first approval beyond non-small cell lung cancer. In a 102-patient Phase 1b/2 trial, the confirmed overall response rate was 42%. Of responders, 56% maintained a response for more than six months. Continued approval may depend on results from the ongoing Phase 3 OrigAMI-5 trial.

Yahoo Finance
Nov 5th, 2026
Four Dividend Kings for retirees: Emerson's 71-year streak leads, Coca-Cola yields 2.2%

Four Dividend Kings, companies that have raised payouts for at least 50 years in a row, stand out for retirees who want growing income, according to a review of dividend safety and cash flow. The four are Emerson Electric, Cincinnati Financial, Johnson & Johnson, and Coca-Cola. Emerson has the longest streak, entering its 71st year after a 7% raise to $0.595 a quarter. The dividend uses about 34% of expected free cash flow, though the stock is the most sensitive to the economy. Cincinnati Financial pays out just 22% of earnings. Johnson & Johnson raised its quarterly dividend 3.1% to $1.34, its 64th straight year of increases. Coca-Cola offers the highest yield, about 2.20%, backed by net debt of 1.3 times EBITDA.

Yahoo Finance
Nov 5th, 2026
Three Dividend Kings could pay $5,581 a year on a $250,000 portfolio

Splitting $250,000 equally across Procter & Gamble, Coca-Cola, and Johnson & Johnson would yield about $5,581 a year in dividends, a blended yield of 2.23%. Each stake would be $83,333.33. All three are Dividend Kings. P&G has raised its payout for 70 straight years, Johnson & Johnson for 64, and Coca-Cola for 63. P&G would pay $2,153.57 a year at a 2.58% forward yield. Coca-Cola would add $1,823.56 at 2.19%, and Johnson & Johnson $1,603.83 at 1.92%. Johnson & Johnson's yield is lowest because its shares have gained 36.74% this year. Coca-Cola's have risen 41.28%, and P&G's 20.95%. Risks include biosimilar competition for Johnson & Johnson's STELARA, Coca-Cola's IRS tax litigation, and P&G's commodity costs of about $1.4 billion after tax.

The Irish Times
Oct 28th, 2026
Johnson & Johnson buys Irish stroke care firm in multimillion euro deal

Sale of Neuravi is largest deal for a venture-backed medtech in Europe since 2009

Recently Posted Jobs

Sign up to get curated job recommendations

Johnson & Johnson is Hiring for 1665 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs